Mercilon

Desogestrel/Ethinylestradiol, the active ingredients in Mercilon, are a combined oral contraceptive presented as a 0.075 mg/0.02 mg tablet for oral use. It prevents pregnancy in women of reproductive age by inhibiting ovulation and altering cervical mucus.

GNH USA supplies Mercilon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mercilon, a combined oral contraceptive, is used within the hormonal contraceptive pathway to prevent pregnancy.

- Contraception: provides reliable protection against unintended pregnancy for women of childbearing potential. - Cycle control: helps achieve more regular menstrual bleeding patterns. - Ovarian cyst reduction: decreases the incidence of functional ovarian cysts in users.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: discomfort or swelling of breast tissue. - Spotting: irregular light bleeding between periods.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins, potentially life‑threatening. - Pulmonary embolism: clot migration to lung vessels causing respiratory distress. - Stroke or myocardial infarction: rare cerebrovascular or cardiac events, especially in high‑risk individuals.

Before initiating Mercilon, patients should be evaluated for contraindications and risk factors. - Contraindicated in pregnancy: product is classified as pregnancy category X and must not be used. - Avoid in smokers over 35 years: increased risk of thromboembolic events. - History of thromboembolism: contraindicated if prior clotting disorders are present. - Monitor blood pressure: hormonal therapy may cause modest elevation. - Store at ambient temperature: keep below 25 °C, in the original pack, protected from moisture.

Mercilon may interact with several medicines that alter hormone metabolism.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): reduce contraceptive efficacy. - Rifampin or other strong CYP3A4 inducers: markedly lower hormone levels. - Protease inhibitors (e.g., ritonavir): may increase hormone concentrations, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Certain antibiotics (e.g., tetracycline, metronidazole): may slightly diminish effectiveness. - St. John’s wort: can lower plasma hormone levels, requiring additional contraceptive measures.